We are thrilled to share exciting updates from eyetec, particularly our active participation in industry-leading events and conferences. As proud members of the Parenteral Drug Association (PDA), eyetec remains committed to staying at the forefront of the latest advancements in pharmaceutical manufacturing. Recently, our co-founder Bram Keymolen had the honor of being one of the speakers at the prestigious PDA Visual Inspection Forum 2022 held in Berlin on 26 and 27 April.
Bram's presentation at the forum focused on the Practical Implications of the revised Annex 1, a pivotal regulatory document that significantly impacts Visual Inspection and Container Closure Integrity Testing (CCIT).
Given the crucial role of visual inspection in ensuring product compliance, particularly in particle detection, the revised Annex 1 introduces new regulatory requirements. Bram, alongside other industry experts, delved deep into these updates, offering valuable insights and perspectives. Moreover, the forum served as a platform to explore emerging topics such as the implementation of Artificial Intelligence and innovative project management approaches for visual inspection.
eyetec is committed to knowledge sharing and collaboration, and we are pleased to offer Bram's presentation on Practical Implications of the revised Annex 1 to interested parties. If you would like to receive a copy of the presentation, please don't hesitate to reach out to us here.
Looking ahead, eyetec is excited to be attending the upcoming PDA Parenteral Packaging Conference in Basel, Switzerland, on 2 and 3 June. We invite you to visit us at tabletop 36, where we will be showcasing our expertise in visual inspection and discussing the latest advancements in the field.
By actively participating in industry events and staying up-to-date with regulatory changes, eyetec remains dedicated to enhancing our knowledge and expertise in visual inspection, particle testing, and other critical aspects of pharmaceutical manufacturing. Together with our valued partners and industry peers, we strive to drive innovation and ensure the highest standards of product quality and patient safety.
Want to receive Bram's presentation on Practical Implications of the revised Annex 1?
